Company profile: IGM Biosciences
1.1 - Company Overview
Company description
- Provider of a proprietary, clinical-stage IgM antibody platform developing engineered IgM therapeutics for cancer, autoimmune and inflammatory diseases. Pipeline includes imvotamab (CD20xCD3) for autoimmune diseases, aplitabart (DR5) for colorectal cancer, and IGM-2644 (CD38xCD3) for autoimmune diseases, all in early trials. Also offers an expanded access program.
Products and services
- Aplitabart: Clinical-stage IgM antibody targeting DR5, currently in Phase 1 trials for colorectal cancer treatment, designed to induce cancer cell death
- Engineered IgM Antibodies: Proprietary platform architects IgM therapeutics leveraging IgM’s natural structure for greater binding power, aiming to improve efficacy and safety versus IgG in cancer, autoimmune, and inflammatory indications
- Imvotamab: Bispecific IgM T cell–engaging antibody targeting CD20 and CD3, in Phase 1b clinical trials for autoimmune diseases including SLE and RA.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IGM Biosciences
Galil Medical
HQ: United States
Website
- Description: Provider of minimally invasive cryotherapy technology and systems for various clinical applications, using compressed Argon gas to freeze and ablate diseased tissue in procedures referred to as cryotherapy, cryoablation, or cryosurgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galil Medical company profile →
ArriVent BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical product development to cure presently untreatable cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArriVent BioPharma company profile →
Day One Bio
HQ: United States
Website
- Description: Provider of targeted therapies for life-threatening diseases, including OJEMDA (tovorafenib), FDA-approved for children with BRAF-altered relapsed or progressive pediatric low-grade glioma; advancing investigational MAPK-pathway inhibitors tovorafenib and pimasertib and conducting FIREFLY-1/2 and FIRELIGHT-1 trials in brain and solid tumors with MAPK pathway aberrations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Day One Bio company profile →
Xcovery
HQ: United States
Website
- Description: Provider of low-toxicity, molecular-targeted oral cancer therapeutics, including Ensartinib for ALK-positive non-small cell lung cancer and Vorolanib, a VEGFR/PDGFR tyrosine kinase inhibitor for solid tumors such as renal cell carcinoma. Conducts clinical trials, seeks partnerships to launch Ensartinib globally and advance Vorolanib in combination therapy, and offers patient information and support resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xcovery company profile →
ImClone Systems
HQ: United States
Website
- Description: Provider of targeted biologic treatments and therapeutic antibodies for oncology, developing a portfolio to address the medical needs of patients with a variety of cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImClone Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IGM Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IGM Biosciences
2.2 - Growth funds investing in similar companies to IGM Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IGM Biosciences
4.2 - Public trading comparable groups for IGM Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →